Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2026)

Amylyx Pharmaceuticals' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 22627.27% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (up 22627.27% YoY), while the FY2025 annual figure was $2.5 million, up 10308.33% from the prior year.
• Other Non-Current Assets was $2.5 million for Q1 2026 at Amylyx Pharmaceuticals, roughly flat from $2.5 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.5 million in Q3 2025 to a low of $11000.0 in Q1 2025.
• Historically, Other Non-Current Assets has averaged $805812.5 across 5 years, with a median of $471000.0 in 2022.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets slumped 97.77% in 2025, then soared 22627.27% in 2026.
• A 5-year view of Other Non-Current Assets shows it stood at $466000.0 in 2022, then jumped by 50.43% to $701000.0 in 2023, then tumbled by 96.58% to $24000.0 in 2024, then jumped by 10308.33% to $2.5 million in 2025, then rose by 0.08% to $2.5 million in 2026.
• The last three Other Non-Current Assets figures came in at $2.5 million (Q1 2026), $2.5 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.